Data figures show that drug maker Siam Bioscience reported a near 50-fold increase in annual profit in 2021, when it began producing AstraZeneca Plc’s COVID-19 vaccine.
The company’s earnings improved sharply last year as it began manufacturing vaccines for the first time.
Profit soared a phenomenal 4,650% to 1.69 billion baht and revenues increased by 1,500% to a record 4.9 billion baht, aided by its contract to manufacture 200 million doses of the Anglo-Swedish firm’s COVID vaccine.
AstraZeneca has affirmed that Siam Bioscience had passed the same quality and capacity checks it conducts on its more than 20 licensed manufacturers worldwide. (NNT)